Jasmine H Hughes
Overview
Explore the profile of Jasmine H Hughes including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
110
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tong D, Hughes M, Hu J, Pearson J, Kubiak D, Dionne B, et al.
Antimicrob Agents Chemother
. 2025 Jan;
69(2):e0104024.
PMID: 39791873
Tobramycin dosing in patients with cystic fibrosis (CF) is challenged by its high pharmacokinetic (PK) variability and narrow therapeutic window. Doses are typically individualized using two-sample log-linear regression (LLR) to...
2.
Hughes M, Lee T, Faldasz J, Hughes J
Pharmacotherapy
. 2024 Oct;
44(10):794-802.
PMID: 39382218
Background: Model-informed precision dosing (MIPD) optimizes drug doses based on pharmacokinetic (PK) model predictions, necessitating careful selection of models tailored to patient characteristics. This study evaluates the predictive performance of...
3.
Hughes M, Hughes J, Endicott J, Langton M, Ahern J, Keizer R
Ther Drug Monit
. 2024 May;
46(5):575-583.
PMID: 38758633
Background: Both parametric and nonparametric methods have been proposed to support model-informed precision dosing (MIPD). However, which approach leads to better models remains uncertain. Using open-source software, these 2 statistical...
4.
Hughes J, Long-Boyle J, Keizer R
J Pharmacokinet Pharmacodyn
. 2024 Mar;
51(3):279-288.
PMID: 38520573
Dose personalization improves patient outcomes for many drugs with a narrow therapeutic index and high inter-individuality variability, including busulfan. Non-compartmental analysis (NCA) and model-based methods like maximum a posteriori Bayesian...
5.
Hughes J, Tong D, Burns V, Daly B, Razavi P, Boelens J, et al.
CPT Pharmacometrics Syst Pharmacol
. 2023 Jul;
12(11):1764-1776.
PMID: 37503916
Consensus guidelines recommend use of granulocyte colony stimulating factor in patients deemed at risk of chemotherapy-induced neutropenia, however, these risk models are limited in the factors they consider and miss...
6.
Hughes J, Woo K, Keizer R, Goswami S
Clin Pharmacol Ther
. 2022 Nov;
113(3):565-574.
PMID: 36408716
Precision dosing aims to tailor doses to individual patients with the goal of improving treatment efficacy and avoiding toxicity. Clinical decision support software (CDSS) plays a crucial role in mediating...
7.
Hughes J, Tong D, Faldasz J, Frymoyer A, Keizer R
Clin Pharmacokinet
. 2022 Nov;
62(1):67-76.
PMID: 36404388
Background And Objective: Infants and neonates present a clinical challenge for dosing drugs with high interindividual variability due to these patients' rapid growth and the interplay between maturation and organ...
8.
Tong D, Hughes J, Keizer R
Pharmaceutics
. 2022 Oct;
14(10).
PMID: 36297524
Model-informed precision dosing (MIPD) can aid dose decision-making for drugs such as gentamicin that have high inter-individual variability, a narrow therapeutic window, and a high risk of exposure-related adverse events....
9.
Hughes J, Keizer R
CPT Pharmacometrics Syst Pharmacol
. 2021 Jul;
10(10):1150-1160.
PMID: 34270885
Model-informed precision dosing (MIPD) approaches typically apply maximum a posteriori (MAP) Bayesian estimation to determine individual pharmacokinetic (PK) parameters with the goal of optimizing future dosing regimens. This process combines...
10.
Hughes J, Tong D, Lucas S, Faldasz J, Goswami S, Keizer R
Clin Pharmacol Ther
. 2020 Oct;
109(1):233-242.
PMID: 33068298
Model-informed precision dosing (MIPD) leverages pharmacokinetic (PK) models to tailor dosing to an individual patient's needs, improving attainment of therapeutic drug exposure targets and thus potentially improving drug efficacy or...